INIS
anticoagulants
100%
patients
61%
plasma
60%
thrombin
53%
concentration
52%
levels
32%
assessments
27%
heparin
25%
reviews
25%
drugs
24%
laboratories
24%
mass spectrometry
19%
humans
17%
sensitivity
16%
range
16%
testing
16%
performance
16%
data
14%
comparative evaluations
14%
urine
14%
information
14%
values
13%
accuracy
13%
risks
13%
validation
13%
in vitro
12%
interactions
12%
recommendations
11%
metabolites
11%
implementation
11%
emergencies
10%
molecular weight
10%
peaks
10%
coagulants
9%
high-performance liquid chromatography
9%
monitoring
8%
control
8%
correlations
8%
specificity
7%
reagents
7%
standardization
7%
applications
7%
hemostatics
7%
venoms
7%
stability
6%
lupus
6%
in vivo
6%
detection
6%
algorithms
6%
thrombosis
6%
thromboplastin
6%
corrections
5%
extraction
5%
hematology
5%
interleukins
5%
dimers
5%
animals
5%
ablation
5%
hemophilia
5%
balances
5%
proteins
5%
guidelines
5%
Pharmacology, Toxicology and Pharmaceutical Science
Direct Oral Anticoagulant
38%
Thrombin
20%
Blood Clotting Factor 10a Inhibitor
18%
Rivaroxaban
15%
Betrixaban
13%
Anticoagulant Agent
13%
Apixaban
9%
Dabigatran
8%
Heparin
8%
Thrombin Inhibitor
8%
Blood Stasis
7%
Low Molecular Weight Heparin
6%
Andexanet Alfa
6%
Venous Thromboembolism
6%
Thrombosis
5%
Dextran Sulfate
5%
Recombinant Interleukin 2
5%
Therapeutic Drug Monitoring
5%
Haemophilia A
5%
Keyphrases
Hokusai
5%
ST Genesia
5%
Analytical Samples
5%
Performance Stability
5%
R2 Score
5%
Mass Spectrometry
5%
Measurement Analysis
5%
Multicenter Trial
5%
Pharmacologically Active
5%
Therapeutic Drug Monitoring
5%
Direct Oral Anticoagulants
5%
Recombinant interleukin-2
5%
In Vivo Animal Studies
5%
Potential Drug Interactions
5%
Peri-procedural
5%
Atrial Fibrillation Ablation
5%
Time to Peak
5%
Common Data Elements
5%
Strip Test
5%
Diagnostic Test Accuracy
5%
Clotting Test
5%
Andexanet Alfa
5%
Anticoagulant Effect
5%
Rivaroxaban
5%
In Vitro Study
5%